ArticleNeuropsychopharmacology reports2022
Correlation of BDNF, VEGF, TNF-α, and S100B with cognitive impairments in chronic, medicated schizophrenia patients.
Article in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The role of TNF signaling pathway in post-stroke cognitive impairment: a systematic review.Annals of medicine · 2025Pooled it
- The Interrelationships between Cytokines and Schizophrenia: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Trial
- Associations between plasma BDNF, VEGF, and EGF and cognition in drug-naïve schizophrenia with and without sleep disturbances.European archives of psychiatry and clinical neuroscience · 2026Article
- Article
- Machine learning helps predict early onset psychosis with serum protein biomarkers, neuropsychometry, and clinicodemographic data.Scientific reports · 2025Article
- Transcriptional evidence of reduced BDNF trophic capacity in the post-mortem human midbrain of schizophrenia cases with high inflammation.Translational psychiatry · 2025Article
- Light Treatment Ameliorates Sub-chronic MK-801-Induced Cognitive Deficits in Mice Through Up-regulating BDNF/p-CREB/p-ERK Signaling Pathway.Molecular neurobiology · 2025Article
- Relationship between reduced serum ceruloplasmin levels and executive dysfunction in hospitalized schizophrenia patients.Frontiers in psychiatry · 2025Article
- Higher plasma neurofilament-light chain concentration in drug-resistant epilepsy.Brain communications · 2025Article
- Article
- Serum Biomarkers to Mild Cognitive Deficits in Children and Adolescents.Molecular neurobiology · 2023Article
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Effects of auriculotherapy on anxiety and biomarkers in Primary Health Care: a clinical trial.Revista brasileira de enfermagem · 2023Article
- Correlation of BDNF, VEGF, TNF-α, and S100B with cognitive impairments in chronic, medicated schizophrenia patients.Neuropsychopharmacology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment is a prominent cause of disability in schizophrenia. Although antipsychotic drugs can rescue the psychotic symptoms, the cognitive impairments persist, with no treatment available. Alterations of BDNF, VEGF, TNF-α, and S100B have been linked to cognitive impairment in several neurological disorders. However, it remains unclear whether their levels are correlated with the cognitive functions of schizophrenia patients. Forty-one chronic, medicated schizophrenia patients were included in this study. Enzyme-linked, immunosorbent assays were used to measure the serum concentrations of BDNF, VEGF, TNF-α, and S100B. Associations between serum protein levels and various domains of the cognitive functions of the schizophrenia patients were observed. We found significant, positive correlations between serum BDNF and the processing speed and attention levels of the patients. Serum VEGF was also positively correlated with their memory and learning functions. In contrast, serum S100B and TNF-α were negatively correlated with the processing speed and attention of the schizophrenia patients. The findings warrant further investigation of these molecules as potential prognostic markers or treatment targets for cognitive impairment in schizophrenia patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.